A review of clinical studies of bestatin.
Bestatin has no clinical toxicity. It increases the number of T cells and enhances NK cell activity. The optimal dose of bestatin was thought to range from 30-100 mg/day/body, and 200 mg/day/body often decreased T-cell number. The clinical effects were as follows: 1) Bestatin alone: possible cure in one case of residual penile tumor after bleomycin treatment; marked regression in two cases of skin metastasis of mammary carcinoma. 2) Radiation and bestatin: complete regression in three cases of Virchow's nodes. 3) Pepleomycin and bestatin: complete regression in one case of metastatic skin adenocarcinoma. 4) Possible favorable effect of bestatin against esophageal carcinoma in combination with radiation and bleomycin.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007167:Immunotherapy; D007930:Leucine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D009369:Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D010412:Penile Neoplasms / Q000188:drug therapy
D000276:Adjuvants, Immunologic; D000903:Antibiotics, Antineoplastic; D007930:Leucine; C012211:ubenimex